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The purpose of this study was to find an antibody that would neutralize the effects of 
meningococcal endotoxins from all capsular serogroups. We were interested in producing 
such an antibody because the capsular vaccines are serogroup-specific, and because there 
is no vaccine available for meningococcus (MGC)  ~ B, Y, or other serogroups that may 
evolve into important pathogens.  When our early unpublished  experiments suggested 
that  antibodies  raised  against  the  lipopolysaccharide  (LPS)  of  one  meningococcal 
serogroup would  not  be uniformly effective against the  LPS of other serogroups,  we 
turned  to antibodies  against Escherichia  coli  JS,  the  mutant  of E.  coli  0111 that  is 
deficient in uridine 5'-diphosphate (UDP)-galactose epimerase. Because this bacterium 
cannot incorporate galactose into its LPS to make complete "0" side chains (1, 2), its core 
is accessible for stimulating antibody production to a wide range of bacteria with similar 
LPS cores. 
Two  separate  lines  of  investigation  from  this  laboratory  encouraged  us  to  test 
antibodies to this mutant E. coli against meningococcal endotoxemia.  First,  we found 
that purifed meningococcal endotoxins were biochemically similar to enteric LPS, but 
were  10  times  more potent  for inducing  the  purpuric,  necrotic lesions  of the  dermal 
Shwartzman phenomenon  (3). This finding appeared to explain the high frequency of 
purpuric skin lesions in meningococcemia, and it provided a convenient way to test the 
effectiveness of antibodies  to  meningococcal  LPS.  Second,  along  with  others  in  this 
laboratory, we showed that antiserum raised against E. coli J5 protected experimental 
animals  against  endotoxemia  and  bacteremia from such  diverse  bacteria  as E.  coli, 
encapsulated Klebsiella, and Pseudomonas aeruginosa  (4-8).  Finally, we reasoned that 
if J5 antibodies could counteract the effects of endotoxemia from diverse enteric bacilli, 
and if meningococcal and enteric LPS were similar both biochemically and biologically, 
antibodies to J5 might also neutralize meningococcal endotoxin. 
Accordingly,  we  compared  antibodies  against  E.  coli  J5  with  antibodies 
against homologous and heterologous meningococcal serogroups for their capac- 
ity to prevent the  dermal and general  Shwartzman  reactions  induced  by LPS 
from MGC A, B, and C. The superiority of antibodies to the E.  coli  mutant in 
these  assays  suggests  that  they  will  counteract  the  effects of meningococcal 
endotoxemia regardless of the capsular serogroup of the infecting strain. 
Materials  and  Methods 
Source of Microorganisms.  Strains of Neisseria  meningitidis  from the collection at Walter 
Reed Army Institute  of  Research, Washington, D. C. were supplied by M. S. Artenstein. Strains 
* Supported by U. S. Army contract PATH/USA/DADA  17-72-C-2040. 
I  Abbreviations  used in this paper: i.v.,  intravenous; LPS, lipopolysaccharide;  MGC, meningo- 
coccus;  PBS, phosphate-buffered saline;  TSB, tripticase  soy broth; UDP, uridine 5'-diphosphate. 
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At, Bil,  and CH were originally  obtained from patients  with meningitis or  meningococcemia, and 
are the prototype strains  used in vaccine studies.  The letter  in the designation of  each strain  of 
MGC  indicates  its  serogroup;  so  that  AI is  serogroup A, Bu is  serogroup B, and CH is  serogroup C. 
E. coli J5, a UDP-galactose epimeraseless mutant of  E. coli 0111,  was originally  described  by 
Elbein and Heath (1).  Our strain  differs  in  that it  is  no longer  capable of  incorporating  galactose 
into  the side  chains of  its  LPS, even when galactose  is  present in the culture  media (7). 
MGC  were stored  in  lyophiles,  rehydrated  with  trypticase  soy broth (TSB), and grown on  blood 
agar overnight at 37°C under CO2. E. coli J5 was stored  on trypticase  soy agar slants  and sub- 
cultured onto blood agar for  24-48 h at  37°C. 
Endotoxins.  Endotoxin was extracted from each strain of MGC by our modification (3) of the 
phenol-water  method  of Westphal  et  al.  (9).  Briefly,  this modification involved growing  the 
cultures  for  3  days,  killing the  cultures  with  a  terminal  concentration  of 1%  formaldehyde, 
discarding the middle layer between the phenol and water layers, and harvesting the endotoxin 
from the upper layer by ultracentrifugation instead of ethanol precipitation. After resuspension 
of the pellet, the material was lyophilized, collected, and weighed. 
As previously described (3), each endotoxin was shown to contain less than 1% protein by the 
method of Folin and Ciocalteu (10), less than 1% RNA by optical density determinations at 280 
and  260  nm,  and  to  be  free  of detectable  capsular  contamination by  the  thiobarbituric acid 
technique of Warren  (11) and by gas-liquid chromatography (2,  3).  The presence of lipid A was 
confirmed by the method of Galanos et al.  (12).  All standards for chemical assays and gas-liquid 
chromatography were of the highest purity available from either Sigma Chemical Co., St. Louis, 
Me., or Calbiochem, San Diego, Calif. 
Immunization.  Bacteria were grown in TSB under CO2 for 48 h, harvested by centrifugation, 
washed three times in 0.15  M  NaC1,  and boiled for 2.5  h.  ARer boiling, the  cells were resus- 
pended  in  0.15  M  NaCI  and  ac~usted  spectrophotometrically  to  a  concentration  of  5  ×  109 
cells/ml.  3-kg rabbits were exsanguinated 7 days after the last of six 1.0-ml intravenous (i.v.) 
injections of boiled cells given three times weekly for 2 wk.  Nonimmune sera was obtained from 
nonimmune littermates. 
Antibody Determinations.  Hemagglutinating antibodies were measured in microtiter plates 
with human group 0 erythrocytes sensitized with the appropriate alkaline-treated endotexin (13). 
Separation and Purification of Immunoglobulins.  30- to 40-ml samples of pooled normal or 
immune rabbit serum were separated into 3 fractions on 5.0 ×  100-cm glass columns packed with 
sterile Sephadex G-200 to a  height of 90 cm. The eluant was phosphate-buffered saline (PBS) at 
pH 7.0, pumped upward from a reservoir by a peristaltic pump at 50-65 ml/h. 10-ml fractions were 
collected in an automatic fraction collector equipped with a  15-watt germicidal lamp. The optical 
density was recorded at 280 nm, and appropriate fractions were combined under sterile conditions. 
Chromatography of immunoglobulin classes was monitored 'by immunodiffusion against heavy- 
chain specific goat anti-rabbit IgM, IgA, and IgG. The frontal peak, which contained pure IgM by 
immunodiffusion, was restored to the original volume by concentration in dialysis tubing against 
polyethylene glycol at 4°C,  and it was stored at 4°C  for animal experiments.  The second peak 
contained  primarily  IgG,  but  was  contaminated  with  small  amounts  of IgA  and  IgM.  After 
concentration, part of this material was stored at 4°C for animal experiments and part was further 
purified. 
The 7S fraction was purified by chromatography over DEAE-Sephadex A-25 by the method of 
Hall et al.  (14). 50- to 100-ml samples were dialyzed against buffer 1 and chromatographed on a 5 
x  25-cm Pharmacia column (Pharmacia Inc., Piscataway, N.J.) packed with 75 g of sterile DEAE- 
Sephadex,  also equilibrated in buffer 1. The protein peak eluted with buffer 1 (0.0175 M PBS at 
pH 6.3) was collected on the automatic fraction collector,  pooled, and concentrated to a  protein 
concentration equal to the original 7S peak (concentrated about 2 × ). This material was pure IgG 
by immunodiffusion and was retained for animal experiments. The second peak was eluted with 
0.4 M PBS, pH 5.3. Before recharging the Sephadex by washing in buffer 1, it was treated with 1 
M NaC1 and 0.1 M NaOH. 
Special  precautions were taken to  assure  sterility as previously described  (4).  All sera and 
immunoglobulin fractions for prevention of the Shwartzman reactions were shown to be sterile 
and free of pyrogens. 
Protection Against Meningoeoccal  Dermal Necrosis (Local Shwartzman Phenomenon).  Skin 
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the intradermal injection of 1.75 ~g in 0.25-ml volumes of MGC A, B, or C endotoxin. The reaction 
was  provoked  21  h  later  by  the  i.v.  injection  of 0.5  ml  of 1.25-1.5  ~g  of the  corresponding 
endotoxin.  Any hemorrhage or necrosis of the skin appearing 4-18 h  after the provocative dose 
was recorded as a positive reaction. Experimental rabbits were given either 20 ml of antiserum or 
15-20 ml of  immune  globulin fractions 19 h after  the preparatory dose (2 h before the provocative 
dose). Control animals received the same volume of  normal rabbit serum or nonimmune  globulin 
adjusted to an equivalent protein concentration. 
Protection Against Meningococcal Renal Cortical Necrosis (Generalized Shwartzman Phenome- 
non).  Groups of 10-20 1.0-1.5-kg rabbits were given 20 ml of either normal or immune serum 3 
days  before they  were  prepared  with  12.5-20  gg of MGC  A,  B,  or  C  endotoxin  i.v.  in 0.5-ml 
volumes. Renal cortical necrosis was provoked 21 h  later by the i.v. injection of 10-12.5/~g of the 
corresponding endotoxin. The animals were sacrificed 2/I h  after provocation, and their kidneys 
were judged positive if  gross hemorrhage or necrosis were present on the external surface. 
Statistical  Methods.  The chi-square test  was used to determine whether or not there was a 
significant difference in the incidence of  Shwartzman  reactions between the groups. 
Results 
Production of  Antiserum.  Rabbits immunized with boiled  cells  ofE. coli  J5 
uniformly caused hemagglutination of  J5-sensitized  erythrocytes to a titer  > 
1:256  by lnicrotiter  and > 1:1,000  by the tube technique. Immunization with  E. 
coli J5 also caused a rise  in hemagglutinins to meningococcal  LPS generally 
equal to  that  obtained by immunization with the homologous MGC. Immuniza- 
tion with heterologous meningococcal  boiled cells  resulted in production of 
hemagglutinins,  but the response was less uniform. The reciprocals  of the 
hemagglutination titers  are shown in Tables I, II, and III.  Although protective 
antisera always contained hemagglutinins,  there was no definite  correlation 
between the height of  the hemagglutinating antibody response and the degree 
of  protection. 
Prevention of Meningococcal  Dermal Necrosis 
MGC A ZN~YrOXlN.  Antiserum to E. coli J5, MGC A, MGC B, and MGC C 
all lowered the incidence of dermal necrosis significantly below that of animals 
which received nonimmune serum (87% positive; Table I). Although antisera to 
J5 and MGC A1 protected a larger percentage of animals (33 and 32% positive), 
they were not statistically more effective than antisera raised against MGC B11 
and Cll (45 and 55% positive). 
MGC B ENDOTOXIN.  Only 28% of  the rabbits given antiserum to J5 developed 
dermal  necrosis,  compared  with  88%  who  received  nonimmune  serum 
(P<0.0005),  and  59%  who  received  heterologous  meningococcal  antiserum 
prepared against MGC A1 (Table II; P=0.01). Antiserum to MGC BI~ (serogroup- 
homologous) was also protective, but not superior to MGC AI antiserum. MGC 
C~I antiserum also protected all but 28% of the animals, but it was not superior 
to MGC A~ or Bll antiserum. 
MGC C ENDOTOXIN.  J5 antiserum protected the largest percentage of rabbits 
in this experiment and was superior to nonimmune and anti-meningococcal A~ 
sera (Table III). Antisera against MGC B~ and CH were also protective. 
COMPOSITE RESULTS.  The results of the experiments shown in Tables I, II, 
and  III  are  combined  in  Table  IV.  In  this  table  the  results  of protection 
experiments with each antiserum against all three meningococcal endotoxins 
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TABLE I 
Prevention of Dermal Shwartzman from MGC A1 Endotoxin with E. 
coli J5 and Meningococcal Antisera* 
Hemagglu-  Number and per- 
Serum  tination  ti-  P value§ 
ter~  cent positive 
Nonimmune  0  52/60 (87)  - 
Anti-MGC A,  128  12/38 (32)  <0.0005 
Anti-E. coli J5  32  10/30 (33)  <0.0005 
Anti-MGC B,,  8  9/20  (45)  <0.0005 
Anti-MGC C,,  8  11/20 (55)  <0.004 
*  The  skin  of 1-1.5-kg  white  New  Zealand  rabbits  was  prepared  with  an 
intradermal injection of 1.75 ~g of MGC A endotoxin in a 0.25-ml volume. 19 
h  later,  20  ml of serum was given in one lateral ear vein, 2 h  before the 
provocative i.v. dose of 1.25/~g of MGC A endotexin in a 0.5-ml volume was 
given in the other ear. Skin sites were examined at 4 and 24 h, and judged 
positive if hemorrhage or necrosis of the skin occurred within 24  h  of the 
provocative dose. 
$ Reciprocal of hemagglutination titer against human group O erythrocytes 
sensitized with alkaline-treated MGC A~ endotoxin. 
§ P  values are in comparison to the normal serum control and were calculated 
by the chi-square technique. 
TABLE  II 
Prevention of Dermal Shwartzman from MGC BI~ Endotoxin with E. 
coli J5 and Meningococcal Antisera* 
Hemagglu-  Number and per- 
Serum  tination  ti-  P value 
ter$  cent  positive 
Nonimmune  0  52/59  (88)  - 
Anti-MGC BI~  32  14/30  (47)  <0.0005 
Anti-E. coli J5  64  11/40 (28)  <0.0005§ 
Anti-MGC A1  32  17/29 (59)  <0.002§ 
Anti-MGC C~  16  5/18  (28)  <0.0005 
*  Experiments were conducted  as  stated  in  the  text  and  in  Table  I  except  that 
B11  endotoxin  was  used  to  prepare  (1.75  ~g)  and  provoke  (1.5  ~g)  the  dermal 
Shwartzman reactions. 
$  Reciprocal  of  hemagglutination  titer  against  human group O erythrocytes 
sensitized  with  alkaline-treated  MGC BH endotoxin. 
§  Protection  by  E. coli  J5 antiserum (28% positive)  was superior  to  that  from 
MGC A~ antiserum  (59% positive),  P<0.01. 
is examined against heterologous as well as homologous LPS. These data show 
that antiserum to  E. coli  J5 was more protective (33% positive)  than nonimmune 
serum  (87% positive; P<0.0005),  MGC  A  antiserum  (51% positive; P<0.015), 
MGC  B antiserum (49% positive,  P<0.03), and MGC  C antiserum (47% positive; 
P<0.06). 
Table V  compares  the results of all protection  experiments with E. coli J5 
antiserum to each meningococcal antiserum tested only against the serogroup- 
heterologous  endotoxins.  In this analysis which  represents  a  more  realistic 
comparison of  the cross-reactivity of  antiserum and LPS, J5 antisera protected C.  E.  DAVIS, E.  J.  ZIEGLER,  AND  K.  F.  ARNOLD 
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Prevention of Dermal Shwartzman from MGC C~1 Endotoxin with E. 
coli J5 and Meningococcal Antisera* 
1011 
Hemagglu-  Number and per- 
Serum  tination  ti-  P value 
ter$  cent positive 
Nonimmune  0  35/40 (88)  - 
Anti-MGC CI~  32  16/30 (53)  <0.002 
Anti-E. coli J5  64  12/30 (40)  <0.0005§ 
Anti-MGC Bl~  16  11/19 (58)  <0.011 
Anti-MGC A~  32  15/20 (75)  No protection§ 
* Experiments were conducted  as  stated  in  the  text  and in  Table I  except  that 
C~ endotoxin  was  used  to  prepare (1.75  ~g)  and provoke (1.5  ~g)  the dermal 
Shwartzman reactions. 
* Reciprocal of  hemagglutination titer  against human group O erythrocytes 
sensitized  with alkaline-treated  MGC  C, endotoxin. 
§ Protection  by  E. coli  J5 antiserum (40% positive)  was superior  to that from 
MGC  AI antiserum (75% positive),  P<0.015. 
TABLE IV 
Prevention  of Dermal Shwartzman from MGC Endotoxins- 
Superiority of E. coli. J5 over MGC Antisera* 
Serum  Number and percent pos-  P values 
itive 
Nonimmune  139/159 (87)  <0.0005 
Anti-E. coli J5  33/100 (33)  - 
Anti-MGC AI  44/87 (51)  <0.015 
Anti-MGC Bll  34/69 (49)  <0.03 
Anti-MGC C.  32/68 (47)  <0.06 
* The results  of  protection  experiments  with  each  serum against endo- 
toxins  of  MGC  A~, Bm  and CH are combined in this  table. 
*  P values compare each serum to the results  obtained with  E. coli  J5 
antiserum. 
a higher percentage of rabbits (33% positive) than did heterologous meningococ- 
cal antisera  (45% positive; P<0.002). 
Prevention of Meningococcal Renal Cortical Necrosis.  E. coli J5 antiserum 
also  prevented  the  renal  cortical  necrosis  of the  generalized  Shwartzman 
reaction,  regardless  of the  serogroup of meningococcal endotoxin.  Tables  VI, 
VII,  and VIII show that the protection afforded by J5 antiserum against renal 
cortical  necrosis  from  MGC  A1  (18%  positive),  MGC  Bll  (30%  positive),  and 
MGC CI~ (22% positive) was significant and at least as effective as that provided 
by homologous antisera.  Heterologous meningococcal antisera did not prevent 
renal cortical necrosis induced by LPS from MGC Bll and C11  (Tables VII and 
VIII). 
Protection with J5 Immunoglobulin Fractions 
PumTY.  The  19S  fractions  of whole  rabbit  serum  chromatographed  over 
Sephadex  G-200  contained  only  IgM  by  immunodiffusion  and  were  used  in 
protection experiments without further purification. Because the 7Sffactions of 1012  NEUTRALIZATION  OF  MENINGOCOCCAL  LIPOPOL¥SACCHARIDE 
TABLE  V 
Prevention of Dermal Shwartzman from Meningococcal 
Endotoxins: Superiority of E. coli J5 over Heterologous 
Meningococcal Antisera* 
Number and percent  pos- 
Serum  itive 
All heterologous  MGC  antisera  68/125 (45)$ 
All  E. coli  J5 antisera  33/100 (33)* 
*  The results  of  protection  experiments with each serum against only 
the serogroup-heterologous endotexins are combined in this table. 
Thus, the results  of J5 antiserum  against all three meningococcal 
endotoxins are compared with the results  of  meningococcal antisera 
tested  only against the endotoxins from the two serogroup-heterolo- 
gous MGC. 
$ E.  coli J5 antiserum  is superior to heterologous MGC  antisera 
(P<0.002). 
TABLE  VI 
Prevention of Renal Cortical Necrosis from MGC A~ Endotoxin 
with E. coli J5 and Meningococcal Antisera* 
Number and percent  P values 
Serum  positive 
Nonimmune  15/36 (42)  - 
Anti-MGC A  7/39  (18)  0.025 
Anti-E. coli  J5  4/39  (10)  0.0025 
* Rabbits received 20  ml of serum 3 days before they were prepared 
with 20  ~g of i.v.  endotoxin. The reaction was provoked 21  h  later 
with 12.5 ~g of i.v. endotoxin. The animals were sacrificed 24 h after 
provocation and kidneys were  judged positive if gross hemorrhage and 
necrosis were present on the external surface. 
$ P  values are in comparison to the normal serum control and were 
calculated by the chi-square technique. 
TABLE  VII 
Prevention of Renal Cortical Necrosis from MGC B H Endotoxin 
with E. coli J5 and Meningococcal Antisera* 
Serum  Number and per-  P value 
cent positive 
Nonimmune  7/8 (88)  - 
Anti-MGC BI~  3/8 (38)  <0.15 
Anti-E.  coli  J5  3/10 (30)  <0.05 
Anti-MGC Cn  6/10 (60)  No protection 
*  Experiments were conducted as stated  in the text  and in Table VI 
except  that  BH endotoxin was used to prepare (12.5  ~g) and provoke 
(10 ~g) renal  cortical  necrosis. 
both nonimmune  and immune  sera showed contaminating  IgA, portions of  each 
were further purified over DEAE-Sephadex  A-25. The first  peak eluted from the 
DEAE-Sephadex  contained only IgG by immunodiffusion  and was stored at 4°C 
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TABLE  VHI 
Prevention of Renal Cortical Necrosis from MGC C11 Endotoxin 
with E. coli J5 and Meningococcal Antisera* 
Serum  Number and per-  P value 
cent positive 
Nonimmune  11/16 (69)  - 
Anti-MGC C11  7/19 (37)  0.06 
Anti-E. coli  J5  4/18 (22)  0.006 
Anti-MGC A~  5/10 (50)  No protection 
* Experiments conducted as stated in the text and in Table VI except 
that C~i endotoxin was used to prepare (15 ~g) and provoke (10 ~g) 
renal cortical  necrosis. 
TABLE  IX 
Prevention  of Dermal Shwartzman from MGC A, Endotoxin 
with Partially Purified Immunoglobulins of E. coli J5 
Antiserum* 
Globulin  Number and per-  P value 
cent positive 
Nonimmune  19S  16/19 (84)  - 
Nonimmune 7S  14/20 (70)  -* 
E. coli J5 19S  14/20 (70)  No protection 
E. coli J5 7S  7/19 (37)  <0.05* 
* Experiments  were conducted as stated in the text and in Table I 
except that 15  ml  of  7S  or  19S  immunoglobulin collected  over Sephadex 
G-200 was tested  instead of  20 ml of  whole serum. 
* E. coli  7S globulin was superior to nonimmune 7S globulin P<0.05. 
Immune 19S was not protective. 
TABLE  X 
Prevention of Dermal Shwartzman from MGC A, Endotoxin 
with Purified Immunoglobulin G of E. coli J5 Antiserum* 
Serum or globulin  Number and per-  P value 
cent positive 
Nonimmune IgG  9/10 (90) 
E. coli J5 Serum  2/10 (20)  <0.003 
E. coli J5 IgG  1/10 (10)  <0.0005 
* Experiments were conducted as stated in the text and in Table I 
except that the 7S fractions  of  Sephadex G-200 were further purified 
over DEAE  Sephadex A-25 and concentrated to  protein  concentrations 
approximately equivalent to that of  the Sephadex G-200 7S fractions. 
Each rabbit was given 20 ml of  either  whole J5 serum or  purified  IgG 
2 h before the provocative dose of  endotoxin. 
1013 
The 19S and 7S fractions from Sephadex G-200 were restored to the original 
volume of the serum before they were used in animal experiments. Normal and 
J5 immune IgG purified over DEAE were concentrated twofold to approximately 
the total protein content of the original 7S Sephadex fractions, before they were 
used in animal experiments. 
PREVENTION  OF  DERMAL  NECROSIS  WITH  IMMUNOGLOBULIN  FRACTIONS.  The 1014  NEUTRALIZATION  OF  MENINGOCOCCAL  LIPOPOLYSACCHARIDE 
results of protection experiments with nonimmune and J5 immune 7S and 19S 
fractions  from  Sephadex  G-200  are  shown  in  Table  IX.  Immune  7S  was 
protective (P<0.05) whether compared to nonimmune  7S, nonimmune  19S,  or 
immune 19S.  Immune 19S was not protective. 
The next experiment shown in Table X compared purified nonimmune and J5 
immune  IgG from  DEAE  Sephadex  with E.  coli J5  antiserum.  Immune  IgG 
(10% positive) was as protective (P<0.005) as whole E. coli J5 antiserum  (20% 
positive; P<0.003) when compared to nonimmune  IgG (90% animals  positive). 
Discussion 
We have shown in these studies that antibodies to E. coli J5, a rough mutant 
of E.  coli  0111,  can  protect  against  the  two most dramatic  manifestations  of 
meningecoccal  endotoxemia:  dermal  purpura  and  renal  cortical  necrosis.  Be- 
cause this mutant is deficient in UDP-galactose epimerase, it cannot build the 
complex "0" antigenic side chains that mask the LPS core of most endotoxins, 
including E. coli 0111 and MGC A1, B11, and C,, This enzymatic block, which is 
equivalent to that of the Rc forms of Salmonella (15), exposes the core so that it 
can stimulate antibodies capable of cross-reactions with all antigenically similar 
endotoxin cores. It is this structural property ofE. coli J5 that is responsible for 
stimulating antibodies that protect against endotoxemia and bacteremia due to 
E. coli (4-7), Salmonella  (4-6),  Klebsiella (7), P. aeruginosa  (8), and meningo- 
coccal LPS,  regardless  of serogroup.  We have  shown previously that  the  "0" 
antigenic side chains, responsible for serogrouping enteric bacilli, interfere with 
antibody  production  to the  antigenically  similar  LPS core.  In  these  studies, 
antibodies to the parental form of J5, E. coli 0111, unlike J5 antibodies,  would 
not protect against diverse gram-negative bacilli such as Klebsiella (7) and P. 
aeruginosa  (8). 
The current  study with  meningococcal LPS shows that  the  oligosaccharide 
side chains  of meningococcal  LPS also interfere  with  serogroup heterologous 
protection. Whereas antibodies to E. coli J5 protected against dermal and renal 
necrosis  induced  by LPS from  MGC  A~,  Bm  and  Cn,  antibodies  to  MGC  A~ 
failed to protect against dermal necrosis or renal cortical necrosis induced by 
MGC Cn LPS (Tables III and VIII). Similarly, MGC C~1 failed to protect against 
renal cortical necrosis induced by MGC B~ (Table VII). Although antiserum to 
MGC A~ prevented dermal necrosis from Bn LPS, this protection was inferior to 
that  from  J5  antibodies  (Table  II).  Finally,  the  protection  by J5  antibodies 
against  dermal  necrosis  induced  by LPS from  all  three  meningococcal  sero- 
groups  was better than  anti-meningococcal  sera,  even  when the  homologous 
endotoxin was included in the calculations (Table IV). The complete absence of 
cross protection in some experiments shows that meningococcal endotoxins are 
antigenically different. Because antibodies to the common core of LPS (E. coli 
J5)  are  completely cross-reactive,  this  antigenic  variability  must  reside  else- 
where in the  LPS complex,  most likely in the "0" antigenic  units.  Antigenic 
variability of "0" side chains is well known among enteric bacilli, but has not 
been generally appreciated in meningococcal LPS, although Zollinger et al. (16) 
showed incomplete serological cross-reactivity of antisera raised against  MGC 
B and C. 
The experiments  with immunoglobulin  fractions  (Table IX and  X) indicate C.  E.  DAVIS,  E.  J.  ZIEGLER,  AND  K.  F.  ARNOLD  1015 
that the protective factor in J5  antiserum is  antibody.  These studies,  which 
show that purified IgG is as effective as whole antiserum, are important because 
a  satisfactory  in  vitro  assay  of cross-reactivity between  J5  antiserum  and 
meningococcal endotoxins  is  not  yet  available.  Our  hemagglutinin  results 
indicate that cross-reactive antibodies were stimulated by immunization with 
J5,  but  there  was  no  definite  correlation  between  the  height  of antibody 
response  and  the  degree  of protection.  More  promising  results  have  been 
obtained with the solid-phase radioimmunoassay. Sadoff et al. (17), have shown 
that J5 antibodies react strongly with all MGC tested in this assay. 
The  failure  of isolated  IgM  to  prevent  dermal  necrosis  is  puzzling.  It  is 
possible that IgM reacts with whole bacteria rather than purified LPS, or that 
IgM antibodies can react only with certain endotoxins. In previous studies of 
immunoglobulin  fractions  directed  against  the  homologous endotoxin,  both 
anti-E,  coli  0111 7S  and  19S  fractions were protective against renal cortical 
necrosis induced by 0111 endotoxin (6). Some antibodies of the IgM class should 
be present at 21  days when immunized rabbits were exsanguinated, but it is 
possible that the concentration of protective antibodies is too low to detect in 
animal assays. 
The demonstration that purified antibodies raised against an E. coli mutant 
can prevent the manifestations of meningococcal endotoxemia suggests that the 
core  of meningococcal endotoxin  is  the  toxic  moiety,  and  underscores  the 
antigenic similarity of LPS from otherwise unrelated bacteria.  Moreover, this 
antibody may provide an additional immunological weapon against meningococ- 
cemia. The pioneering work of Goldschneider et al.  (18) and Gotschlich et al. 
(19, 20) at Walter Reed has provided capsular vaccines that prevent meningo- 
coccal disease caused by MGC of groups A  and C  (21-23).  Unfortunately, this 
protection is serogroup-specific. Group B capsule is not immunogenic in man 
(24), and there is no vaccine available for serogroup Y or other groups that may 
evolve into  important pathogens.  Because of the serogroup specificity of the 
capsular vaccines, the nonimmunogenicity of group B capsule, and the patho- 
genic potential of other meningococcal serogroups, investigators have turned to 
studies of outer membrane antigens that might cross-react between capsular 
groups (16, 25-27).  These studies have resulted in the identification of a number 
of different outer membrane serotypes that cross serogroup lines. The protective 
capacity of serotype antibodies against group B strains tested in chick embryos, 
however, appears to be serogroup-specific (28); in other words, antisera raised 
against whole MGC  B  of different serotypes showed primarily group-specific 
protection. Serogroup and serotype antibodies did appear to provide synergistic 
protection against the homologous serogroup. 
On the other hand, antiserum raised against E. coli J5 protects rabbits from 
meningococcal endotoxemia regardless of serogroup. Similarly, gamma globulin 
prepared from these broad-spectrum antibodies should counteract the devastat- 
ing effects of meningococcal endotoxemia in patients infected with any capsular 
serogroup. 
Summary 
Antibodies to Escherichia coli J5, a uridine 5'-diphosphate-galactose epimerase- 
less mutant of E.  coli  0111, neutralized meningococcal endotoxemia from all 1016  NEUTRALIZATION  OF  MENINGOCOCCAL LIPOPOLYSACCHARIDE 
three  major  capsular  serogroups.  We  chose the  dermal  necrosis of the  local 
Shwartzman  phenomenon  and  the  renal  cortical  necrosis  of  the  general 
Shwartzman phenomenon as assays because these are the hallmarks of menin- 
gococcemia, and because meningocoecal lipopolysaccharide (LPS) is a uniquely 
potent cause  of dermal  purpura  and  necrosis.  Meningococcal antisera  raised 
against  LPS  from  MGC  A,  B,  and  C  also  provided good  protection against 
endotoxemia from  the  homologous capsular  groups,  but  it  was  inconsistent 
against the heterologous serogroups. The superiority of J5 antibodies (purified 
IgG as well as antiserum) is probably due to the fact that J5 LPS contains only 
the endotoxin core. Consequently, immunization with this mutant stimulates 
production of antibodies to core LPS without interference by the 't0" antigenic 
determinants of the side chains. 
These observations indicate  that  the  endotoxin core is  the  toxic moiety of 
meningococcal LPS, that the core LPS of meningococcus (MGC) is immunologi- 
cally similar to enteric LPS, and that the antigenically variable "0" side chains 
of MGC LPS interfere with antibody production against the common core. They 
also suggest that antibodies prepared against this E. coli mutant could interrupt 
the devastating course of meningococcal endotoxemia in man, regardless of the 
capsular serogroup of the infecting strain. 
Received for publication 30 November 1977. 
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